Navigation Links
ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
Date:10/19/2010

RANCHO CORDOVA, Calif., Oct. 19 /PRNewswire/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today it has entered into a license and distribution agreement for its Res-Q™ 60 BMC (Res-Q) System with BioParadox, Inc., a newly-formed regenerative medicine company focusing on point-of-care cardiovascular therapies.

Under the agreement, ThermoGenesis is granting BioParadox exclusive worldwide rights for use of the Res-Q technology to automate the preparation of PRP from peripheral blood, subject to BioParadox meeting certain milestones, including initiation and completion of clinical trials to support claims and maintain the rights.

The Res-Q is a point-of-care system designed for the preparation of cell concentrates. The device, in its current configuration, is used to process stem cells from bone marrow aspirate. With a minor modification, the device design also produces PRP from peripheral blood.  ThermoGenesis has filed a form 510(k) with the FDA seeking market clearance for use of the Res-Q System technology in the preparation of PRP from peripheral blood.

"We are looking forward to our collaboration with BioParadox and believe this agreement represents a milestone in our initiative to create novel applications for our proprietary Res-Q technology," said J. Melville Engle, Chief Executive Officer of ThermoGenesis.

"We have demonstrated in our laboratories that the Res-Q technology is well suited for the preparation of PRP, and expect to file our follow up 510(k) submission to the FDA within the next two weeks. The PRP market continues to grow and this agreement places ThermoGenesis and BioParadox in the middle of this emerging field," he added.

The agreement between the parties was filed as an exhibit to Form 8-K by the Company, and the foregoing is qualified by the terms of the agreement and disclosure in the Form 8-K, which can be viewed through the Company's website.

About ThermoGenesis Corp.ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress™ Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP™ MarrowXpress™ and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
  • The Res-Q™ 60 BMC (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
  • The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

  • This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2011, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2011.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.ThermoGenesis Corp.Web site: http://www.thermogenesis.comContact: Investor Relations+1-916-858-5107, orir@thermogenesis.com
    '/>"/>

    SOURCE ThermoGenesis Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
    2. ThermoGenesis Announces National Institute of Health Grant
    3. ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program
    4. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
    5. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
    6. ThermoGenesis Regains Compliance With NASDAQ Listing Rules
    7. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
    8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/10/2016)... , February 10, 2016 A ... which will be held at Victoria Park Plaza in ... an informative seminar on technology and future advances for late ... led by Lorna Graham , associate director of project ... to keep up with new regulations and standards in late ...
    (Date:2/10/2016)... Puerto Rico Healthcare and Life Sciences Report 2016 ... Report 2016 . --> Focus Reports releases ... Sciences Report 2016 . pharmaceuticals , or ... world for pharma manufacturing, a territory with significantly improved capabilities ... per square mile than anywhere else on the planet. ...
    (Date:2/10/2016)... , Feb. 10, 2016 Convergence ... confluence of various technologies that results in ... unavailable. These opportunities create a cyclical system ... turn, drives the development of new technologies. ... characterized by technology convergences, which are constantly ...
    Breaking Medicine Technology:
    (Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... medical dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and ... Indicator sensor for resistance cord exercise and therapy, introduces its new microFET Digital ...
    (Date:2/11/2016)... , ... February 11, 2016 , ... As part of ... of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to University of ... Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support a promising ...
    (Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and ... in order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige ... Clio, only 15 miles away from Flint. , “We have deep roots in the ...
    (Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting ... Healthcare, recently partnered with Heart City Health Center to improve access ... years, Heart City Health Center has provided the Elkhart community with access to ...
    (Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is ... leading bottled water brand owners that topped the list as a result of their ... conversion. The premier brand was Tibet 5100, a top notch water company that specializes ...
    Breaking Medicine News(10 mins):